TEVA News and Press, Teva Pharmaceutical Industries Limited American Depositary Shares

2026-03-10 10:30:17 ET Teva Pharmaceutical Industries Limited (TEVA) Barclays 28th Annual Global Healthcare Conference March 10, 2026 8:00 AM EDT... Read the full article on Seeking Alpha For further details see: Teva Pharmaceutical Industries Limited (TEVA) Presents at Barc...

2026-03-09 16:28:02 ET Teva Pharmaceutical Industries Limited (TEVA) Leerink Global Healthcare Conference 2026 March 9, 2026 10:00 AM EDT... Read the full article on Seeking Alpha For further details see: Teva Pharmaceutical Industries Limited (TEVA) Presents at Leerink Glob...

2026-03-09 06:44:09 ET The U.S. Food and Drug Administration is reportedly easing some requirements for drugmakers developing copycat versions of costly biologic medications in a bid to bring more competition to the market and lower costs. The agency plans to reduce the need f...

2026-03-06 14:20:00 ET Numerous factors are affecting the stock market right now. However, many long-term opportunities remain. Some stocks benefit from current trends, whether they be rising spot gold prices or accelerating adoption of generative artificial intelligence (AI). There are...

2026-03-04 14:07:00 ET Change is exciting, and it comes with risks. This is why turnaround stocks are so interesting. Right now, Teva Pharmaceutical Industries (NYSE: TEVA) is a turnaround story that may appeal to investors. But if you like dividends, you'll probably prefer this dru...

2026-03-04 04:26:00 ET Two weeks ago, on Feb. 17, institutional investors with at least $100 million in assets under management were required to file Form 13F with regulators. A 13F is an invaluable data set that allows investors to track which stocks and exchange-traded funds (ETFs) Wa...

2026-03-03 17:32:49 ET More on Teva Pharmaceutical Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Results - Slideshow Teva Pharmaceutical Industries Limited (TEVA) Discusses Duvakitug IBD Phase 2b Maintenance Top-Line Resu...

Blackstone Life Sciences will provide $400 million to support development of duvakitug, a human monoclonal antibody targeting TL1A Duvakitug is currently in phase 3 clinical studies for ulcerative colitis (UC) and Crohn’s disease (CD) Agreement supports Teva’s Pivot to Growth stra...

2026-03-03 10:18:00 ET ... Read the full article on Seeking Alpha For further details see: Baron Health Care Fund Q4 2025 Contributors And Detractors

2026-03-02 15:20:00 ET When you think "top-performing pharma stock," Eli Lilly may first come to mind. Yet while Lilly's shares have surged over the past few years, they've only gained around 14% over the past year. Contrast that with Teva Pharmaceutical Industries (NYSE: TEVA...